Japan· JP-4291439A1027
リツキシマブ（遺伝子組換え）［リツキシマブ後続１］
A medicinal product containing リツキシマブ（遺伝子組換え）［リツキシマブ後続１］, registered in Japan by サンド, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- リツキシマブ（遺伝子組換え）［リツキシマブ後続１］
- Manufacturer
- サンド
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
リツキシマブ（遺伝子組換え）［リツキシマブ後続１］ in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- United KingdomItuxredi 100mg/10ml concentrate for solution for infusion vialsDr Reddy's Laboratories (UK) Ltd
- CzechiaBLITZIMACelltrion Healthcare Hungary Kft., Budapest
- BelgiumBlitzima 100 mgCelltrion Healthcare Hungary
- SwedenBlitzima 100 mg Koncentrat till infusionsvätska, lösningCelltrion Healthcare Hungary Kft
- NetherlandsBlitzima 100 mg, concentraat voor oplossing voor infusieCelltrion Healthcare Hungary Kft.
- IcelandBlitzimaCelltrion Healthcare Hungary Kft.
- PolandBlitzimaCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ituxredi
- Iceland · Blitzima, Mabthera
- Liechtenstein · Blitzima, Mabthera
- Norway · Blitzima, Mabthera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b27b085f-e17f-4fce-88e2-c97993ad9338 GET /v1/drugs/b27b085f-e17f-4fce-88e2-c97993ad9338?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００ｍｇ１０ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291439A1027",
"category": "注射薬",
"price_yen": 9274,
"generic_name": "リツキシマブ（遺伝子組換え）［リツキシマブ後続１］",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about リツキシマブ（遺伝子組換え）［リツキシマブ後続１］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.